Arvinas (NASDAQ:ARVN) Now Covered by Stephens

Stephens started coverage on shares of Arvinas (NASDAQ:ARVN - Free Report) in a research note issued to investors on Monday, MarketBeat reports. The firm issued an overweight rating and a $55.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright restated a "buy" rating and set a $87.00 price target on shares of Arvinas in a research note on Thursday, October 31st. Wedbush reaffirmed an "outperform" rating and issued a $57.00 price target on shares of Arvinas in a report on Tuesday, July 30th. Oppenheimer dropped their price objective on shares of Arvinas from $50.00 to $40.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. Barclays reduced their target price on Arvinas from $60.00 to $48.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research note on Monday, September 9th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $59.62.

Arvinas Stock Up 3.2 %

Shares of Arvinas stock traded up $0.71 on Monday, reaching $23.19. The stock had a trading volume of 775,435 shares, compared to its average volume of 716,033. The stock has a market capitalization of $1.59 billion, a P/E ratio of -4.70 and a beta of 1.96. The company has a 50 day moving average price of $25.78 and a 200 day moving average price of $27.24. Arvinas has a 1 year low of $20.28 and a 1 year high of $53.08.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. The business's revenue for the quarter was up 196.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.18) earnings per share. On average, analysts forecast that Arvinas will post -3.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Arvinas in the 2nd quarter valued at about $42,000. nVerses Capital LLC acquired a new position in shares of Arvinas during the 3rd quarter worth approximately $39,000. Amalgamated Bank raised its stake in shares of Arvinas by 29.6% during the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company's stock worth $59,000 after buying an additional 508 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after buying an additional 440 shares in the last quarter. Finally, Quantbot Technologies LP grew its stake in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after acquiring an additional 2,601 shares during the period. Institutional investors and hedge funds own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.